Phase II Study of Lenalidomide in Combination with Rituximab as Initial Therapy for Mantle-Cell Lymphoma


Phase II Study of Lenalidomide in Combination with Rituximab as Initial Therapy for Mantle-Cell Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Ruan J et al. Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: Multi-center Phase II study of lenalidomide plus rituximab. Proc ASH 2013;Abstract 247.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.